753 related articles for article (PubMed ID: 11040070)
21. IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis.
Horváth B; Niedermeier A; Podstawa E; Müller R; Hunzelmann N; Kárpáti S; Hertl M
Exp Dermatol; 2010 Jul; 19(7):648-53. PubMed ID: 20500772
[TBL] [Abstract][Full Text] [Related]
22. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.
Fairley JA; Fu CL; Giudice GJ
J Invest Dermatol; 2005 Sep; 125(3):467-72. PubMed ID: 16117787
[TBL] [Abstract][Full Text] [Related]
23. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease.
Izumi R; Fujimoto M; Yazawa N; Nakashima H; Asashima N; Watanabe R; Kuwano Y; Kurokawa M; Hashimoto T; Tamaki K
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S94-7. PubMed ID: 17434049
[TBL] [Abstract][Full Text] [Related]
24. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity.
Oyama N; Setterfield JF; Powell AM; Sakuma-Oyama Y; Albert S; Bhogal BS; Vaughan RW; Kaneko F; Challacombe SJ; Black MM
Br J Dermatol; 2006 Jan; 154(1):90-8. PubMed ID: 16403100
[TBL] [Abstract][Full Text] [Related]
25. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases.
Schumann H; Baetge J; Tasanen K; Wojnarowska F; Schäcke H; Zillikens D; Bruckner-Tuderman L
Am J Pathol; 2000 Feb; 156(2):685-95. PubMed ID: 10666397
[TBL] [Abstract][Full Text] [Related]
26. The 120-kDa soluble ectodomain of type XVII collagen is recognized by autoantibodies in patients with pemphigoid and linear IgA dermatosis.
Roh JY; Yee C; Lazarova Z; Hall RP; Yancey KB
Br J Dermatol; 2000 Jul; 143(1):104-11. PubMed ID: 10886143
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
28. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid.
Sakuma-Oyama Y; Powell AM; Oyama N; Albert S; Bhogal BS; Black MM
Br J Dermatol; 2004 Jul; 151(1):126-31. PubMed ID: 15270881
[TBL] [Abstract][Full Text] [Related]
30. Assessment of skin basement membrane zone antibodies in the urine of patients with acquired subepidermal immunobullous diseases.
Allen J; Shears E; Powell J; Wojnarowska F
Br J Dermatol; 2001 Mar; 144(3):540-5. PubMed ID: 11260011
[TBL] [Abstract][Full Text] [Related]
31. Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses.
Laffitte E; Skaria M; Jaunin F; Tamm K; Saurat JH; Favre B; Borradori L
Br J Dermatol; 2001 Apr; 144(4):760-8. PubMed ID: 11298534
[TBL] [Abstract][Full Text] [Related]
32. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
Front Immunol; 2019; 10():1934. PubMed ID: 31474998
[TBL] [Abstract][Full Text] [Related]
33. Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases.
Csorba K; Schmidt S; Florea F; Ishii N; Hashimoto T; Hertl M; Kárpáti S; Bruckner-Tuderman L; Nishie W; Sitaru C
Orphanet J Rare Dis; 2011 May; 6():31. PubMed ID: 21619684
[TBL] [Abstract][Full Text] [Related]
34. Two cases of childhood bullous pemphigoid.
Toyama T; Nakamura K; Kuramochi A; Ohyama B; Hashimoto T; Tsuchida T
Eur J Dermatol; 2009; 19(4):368-71. PubMed ID: 19451055
[TBL] [Abstract][Full Text] [Related]
35. Detection of IgG and IgE reactivity to BP180 using the ISAC® microarray system.
Pomponi D; Di Zenzo G; Zennaro D; Calabresi V; Eming R; Zuzzi S; Bernardi ML; Scala E; Mari A
Br J Dermatol; 2013 Jun; 168(6):1205-14. PubMed ID: 23252883
[TBL] [Abstract][Full Text] [Related]
36. Parallel fluctuation of anti-desmoglein 3 and anti-BP180 autoantibody titres in a patient with bullous pemphigoid.
Takahashi H; Anzai H; Suzuki Y; Tanikawa A; Amagai M; Nishikawa T
Clin Exp Dermatol; 2004 Nov; 29(6):608-11. PubMed ID: 15550133
[TBL] [Abstract][Full Text] [Related]
37. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180.
Zillikens D; Caux F; Mascaro JM; Wesselmann U; Schmidt E; Prost C; Callen JP; Bröcker EB; Diaz LA; Giudice GJ
J Invest Dermatol; 1999 Jul; 113(1):117-21. PubMed ID: 10417629
[TBL] [Abstract][Full Text] [Related]
38. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
Döpp R; Schmidt E; Chimanovitch I; Leverkus M; Bröcker EB; Zillikens D
J Am Acad Dermatol; 2000 Apr; 42(4):577-83. PubMed ID: 10727301
[TBL] [Abstract][Full Text] [Related]
39. BP180 as the common autoantigen in blistering diseases with different clinical phenotypes.
Zillikens D
Keio J Med; 2002 Mar; 51(1):21-8. PubMed ID: 11951375
[TBL] [Abstract][Full Text] [Related]
40. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
